Announcement of Results of Phase II Randomized Clinical Trial of Taiho Pharmaceutical’s Novel Antitumor Agent TAS-102
At the 9th Annual Meeting of the Japanese Society of Medical Oncology held in Yokohama, Taiho Pharmaceutical Co. Ltd, with
Read more